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Abstract
Background: The implementation of highly active antiretroviral therapy (HAART) among HIV-positive patients
results in immune reconstitution, slower progression of HIV disease, and a decrease in the occurrence of
opportunistic infections. However, the impact of HAART on cervical human papillomavirus (HPV) infection,
clearance, and persistence in high-risk adolescents remains controversial.
Methods: HIV-positive and high-risk HIV-negative female adolescents were enrolled in the Reaching for Excellence
in Adolescent Care and Health (REACH) longitudinal cohort study. At each semi-annual clinical visit, cervical lavage
samples were tested for 30 HPV types. Type-specific and carcinogenic risk-specific HPV prevalence and incidence
were compared in 373 eligible participants: 146 HIV-negative female adolescents with a median follow-up of 721.5
[IQR: 483-1301] days and 227 HIV-positive female adolescents. Of the 227 HIV-positive participants, a fixed set (n =
100) were examined both before and after HAART initiation; 70 were examined only before HAART initiation; and
57 were examined only after HAART initiation, with overall median follow-up of 271 [IQR: 86.5-473] and 427.25 [IQR:
200-871] days respectively for before and after HAART initiation.
Results: Of the 373 eligible participants, 262 (70%) were infected with at least one type of HPV at baseline, and 78
of the remaining 111 (70%) became infected with at least one type of HPV by the end of the study. Overall, the
incidence and prevalence of HPV types 58, 53/66, 68/70, and 31/33/35 were much higher than the established
carcinogenic and HPV vaccine types 16 and 18, especially in HIV-positive females both before and after HAART
initiation. Baseline prevalence for individual high-risk HPV types ranged, depending on type, from 0.7-10%, 1-17%,
and 1-18% in the HIV-negative group, the HIV-positive before HAART initiation group, and the HIV-positive after
HAART initiation group, respectively. Likewise, the incidence ranged, depending on HPV type, from 0.64-9.83 cases/
100 PY, 3.00-12.80 cases/100 PY, and 1.49-17.05 cases/100 PY in the three groups, respectively. The patterns of each
HPV type infection, clearance, and persistence did not differ considerably before or after the introduction of HAART
and were clearly independent of CD4+ change within the short post-HAART follow-up period.
Conclusions: HAART did not immediately affect the incidence of type-specific HPV infections within a short-period
follow-up; however, future studies are warranted in larger populations to evaluate HAART’s impact over longer
periods.
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Background
Human papillomavirus (HPV) infection is the most pre-
valent sexually transmitted infection (STI) in the United
States (U.S.) and the world [1,2]. In the NHANES sur-
vey, the overall HPV prevalence was 24.5% (95% CI,
19.6%-30.5%) among females aged 14-19 years [3]. Of
the estimated 20 million infected persons in the U.S.,
about half are 15-24 years old; another 6.2 million new
cases (4.6 million aged 15-24) are diagnosed annually
[4]. Furthermore, an estimated 80% of all sexually active
females will have been exposed to HPV by age 50 [5].
The medical care cost for HPV-related conditions
(including abnormal Pap smears and treatment for cer-
vical neoplasia and cancer) is over $3.5 billion per year–
greater than for all other common STIs except HIV/
AIDS [6]. Although most infected individuals (70-90%)
naturally clear an HPV infection within 12-24 months,
the virus persists in a subset of infected hosts [7-9]. An
infection that has persisted for more than four years has
only a small chance of remission [10]. Persistent HPV
infection, along with environmental and genetic factors,
predisposes individuals to the development of high-
grade cervical intraepithelial neoplasia (CIN) [11] and,
in some cases, to subsequent progression to cancer [12].
Other clinical manifestations of HPV infection include
anogenital warts and recurrent respiratory papillomato-
sis, as well as anal, vulvar, vaginal, penile, and head and
neck cancers.
HIV-negative females effectively clear cervical HPV
infections 4-10 times more frequently than HIV-positive
females, with the lowest rate of clearance among
severely immunocompromised females with CD4+ T-cell
(CD4+) counts <200 (cells/mm3) [13-15]. A previous
study among participants of the Reaching for Excellence
in Adolescent Care and Health (REACH) cohort sug-
gested that the frequency of HPV persistence varied
inversely with CD4+ count [16]. Likewise, other studies
have found higher HPV prevalence and incidence of
oncogenic HPV types in HIV patients, especially those
with lower CD4+ counts, compared to HIV-negative
individuals [13,17,18]. These data suggest that the level
of CD4+ is important in the pathogenesis of HPV infec-
tion in HIV patients.
The cervical cancer incidence among HIV-infected
females in the U.S. is higher (86.5 cases per 100,000 per-
son-years [PY]) since the introduction of HAART (1996-
2002) than it was in 1990-1996 (64.2 cases per 100,000
PY), although the difference is not statistically significant
(relative risk [RR] = 1.41, 95% CI = 0.81 to 2.46) [19].
This could be attributed to the fact that, in the HAART
era, most HIV-positive females live longer and thus the
cumulative prevalence of cervical cancer could be
higher. The widespread use of HAART, resulting in
immune reconstitution for HIV-positive patients, has led
to a decrease in the incidence of opportunistic infections
and HIV-related malignancies such as Kaposi’s sarcoma
and non-Hodgkins lymphoma. However, no association
between CD4+ count and cervical cancer incidence was
observed in either period in the same study [19]. Clearly,
females with AIDS have an increased risk of cervical
cancer, but whether this risk is related to immunosup-
pression or simply reflects a higher risk of acquiring
human papillomavirus in the same population is
unclear.
Studies of the impact of HAART on the natural his-
tory of HPV infection and HPV-related diseases, how-
ever, are limited and inconsistent [20]. While some
studies show clear reductions in progression of lesions
or disease [21-25], others have shown negative or no
effects [26-30]. Most studies examining the effect of
HAART on HPV-related outcomes have focused on cer-
vical precursor lesions or cancer, but not on HPV clear-
ance or persistence. With the increase of CD4+ T-cells
and the decrease in HIV viral load through HAART
therapy, immune reconstitution as a result of HAART
may be associated with the clearance of HPV infection.
In this report, the immediate effect of HAART on the
incidence, persistence, and clearance of type-specific
HPV among HIV-positive female adolescents is
examined.
Methods
Study population
Participants in this analysis were HIV-positive and HIV-
negative female adolescents enrolled in the Reaching for
Excellence in Adolescent Care and Health (REACH)
study. The study design and methods for quarterly fol-
low-up, HIV-1 testing, immunophenotyping of CD4+
counts, and collection of biological specimens along
with demographic, risk behavior, and other clinical data
for this cohort have been previously described in detail
[31,32]. Briefly, adolescents aged 12-19 years who
acquired HIV-1 through sexual activity or injection drug
use (perinatal transmission or blood product contamina-
tion were excluded) and comparable high-risk seronega-
tives were recruited between February 1996 and
November 2000 and followed up with until December
2000 in a longitudinal study at 15 clinical sites in the U.
S. to investigate the natural history of HIV [33]. Of the
548 adolescents enrolled in the REACH study, 355 were
HIV-seropositive (71% African-Americans, 75% females,
91% with CD4+ ≥200 at baseline), and two sero-con-
verted and were excluded from the study. We included
follow-up data from all HIV-negative and HIV-positive
female adolescents off HAART (HAART-naïve through-
out the study or until initiation) and follow-up data
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from all HIV-positive female adolescents initiating
HAART during the REACH study.
For the case-crossover sub-study, we included only
HIV-positive female adolescents who were HAART-
naïve at enrollment but initiated HAART during the
course of the study, providing adequate follow-up peri-
ods before and after the introduction of HAART
(referred to as before HAART initiation and after
HAART initiation). This allows for internal controlling
of potential confounders. Therefore, those who self-
reported previous initiation of HAART or had chart
documentation of HAART initiation prior to enrolling
in the REACH cohort, as well as those who did not
initiate HAART during the study, were excluded from
this sub-study sensitivity analysis. All the participants
provided written informed consent in the parent study,
and the UAB Institutional Review Board approved this
sub-study.
HAART Treatment
Participants who were prescribed HAART, consistent
with the Public Health Service Guidelines for the Use of
Antiretroviral Agents in HIV-Infected Adults and Ado-
lescents [34], were included in the analysis. At the time
of the study visit, HAART was defined as a combination
of two nucleoside reverse transcriptase inhibitors and
either a protease inhibitor or a non-nucleoside reverse
transcriptase inhibitor, or a zidovudine/lamivudine com-
bination regimen plus another antiretroviral drug. HPV
data from the last study visit before the initiation of
HAART were used as baseline values for comparison to
after HAART initiation values in the subset group. Data
on antiretroviral therapy were obtained through inter-
view and chart review for current prescriptions, and
adherence data were obtained through interviews as pre-
viously described [35]. Participants were censored at the
end of the study, or at the last available visit or the first
visit that they reported not adhering to the HAART
regimen.
HPV DNA Detection
At enrollment and every six months thereafter, cervical
lavage samples were tested for the presence of HPV. In
brief, viral DNA fragments from the samples were
amplified by use of consensus primers MY09/11 and
HMB01 and hybridized with a consensus probe and 30
different HPV strain-specific probes (some probes were,
however, specific for more than one HPV type) by use
of a chemiluminescent dot-blot format [36]. PCR-based
HPV data were classified as follows: negative; positive
for the specific types; or “positive, type unknown” if the
sample was positive for the generic probe but not for a
specific HPV type. PCR amplification of the human
b-globin gene segment was used as an internal control
for DNA quality, and samples negative in this assay
were excluded from analyses. There were 21 b-globin
negative observations among HIV-negative female ado-
lescents, of whom four were HPV-positive; nine among
HIV-positive female adolescents who were never on
HAART, of whom two were HPV-positive; and 38 dur-
ing HAART, of whom three were HPV-positive. For
analytic purposes, HPV types also were categorized
according to risk groups [37,38] and by vaccine cover-
age: i) high-risk carcinogenic (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68); ii) possible carcinogenic (26,
53, 66, 67, and 69); iii) low-risk (2, 6, 11, 13, 32, 40, 42,
44, 54, 55, 57, 62, and 72); and iv) bivalent vaccine type
(16 and 18).
Before and After HAART Initiation Period
The before HAART initiation follow-up duration was
estimated from the date of enrollment to the last visit
before starting HAART. After HAART initiation follow-
up included the time from the start date of HAART to
either the end of the REACH study, the last visit before
HAART was stopped, the visit at which the patient self-
reported not adhering to HAART, or when the patient
was lost to follow-up–whichever was applicable.
Statistical Analysis
Baseline prevalence and incidence of type-specific HPV
infections were estimated and compared among differ-
ent groups within the REACH cohort: 1) before HAART
initiation period only; 2) after HAART initiation period
only; 3) HIV-negatives; and 4) a case-crossover subset
with both before and after HAART initiation periods.
Cumulative prevalence was defined as the percent of
female adolescents with an HPV infection detected at
either the baseline or at one of the follow-up visits. The
type-specific HPV incidence per 100 PY, along with 95%
confidence intervals (95% CI), were estimated before
and after HAART initiation, and statistical differences
were reported with p-values using chi-square tests. To
contribute person-time to the before HAART initiation
incidence analyses, participants were required to be
HPV-negative for a specific HPV strain at baseline, and
for after HAART initiation incidence analyses, partici-
pants had to be HPV-negative for a specific HPV strain
from the before HAART initiation period until the start
of HAART. Since exact infection dates are not known,
the midpoint between the last HPV-negative visit and
the first HPV-positive visit date was used as the esti-
mated infection incident date for calculation of person-
time at risk. Time elapsed following the HPV incidence
date was not included in estimates of person-time at
risk. However, for participants testing negative for a spe-
cific HPV type during the before and after HAART
initiation periods, person-time was estimated from the
Shrestha et al. BMC Infectious Diseases 2010, 10:295
http://www.biomedcentral.com/1471-2334/10/295
Page 3 of 11
beginning through the end of the study in the two peri-
ods, respectively. Participants co-infected with different
HPV types were analyzed separately for each HPV type.
The prevalence and incidence by HIV status and before
and after HAART initiation periods were compared.
We also compared the CD4+ counts of the before
HAART initiation infection with after HAART initiation
clearance (the average CD4+ counts from the last HPV-
positive before HAART initiation visit and the first of
the two consecutive HPV-negative visits after infection
in the after HAART initiation for all HPV types), persis-
tence (the average CD4+ during all infected visits before
and after HAART initiation, and for new infection (aver-
age CD4+ counts from the last HPV-negative visit before
HAART initiation and the first HPV-positive visit after
HAART initiation).
Results
There were a total of 373 eligible female adolescent par-
ticipants (146 HIV-negative and 227 HIV-positive) in
the REACH cohort, of whom 262 (70%) were infected
with at least one HPV type at baseline. Of the remaining
111 not infected with HPV at baseline, 78 (70%) became
infected with at least one type of HPV by the end of the
study. Of the HIV-positives, 192 were HAART-naïve at
enrollment but initiated HAART while participating in
the REACH study; 62 started HAART on the first visit
and lacked before HAART initiation follow-up; 22 had
missing dates for the initiation of HAART; and seven
lacked adequate follow-up data after HAART initiation.
The prevalence and incidence estimates were based on
146 HIV-negative females, 170 for the before HAART
initiation period (100 of whom initiated HAART during
the study and were censored up until that date, and
another 70 who were never on HAART), and 157 for
the after HAART initiation period (57 of whom initiated
HAART immediately after enrollment and therefore
contributed no before HAART initiation data, and the
100 in the case-crossover subset with at least two fol-
low-up visits before and after HAART with HPV data).
There were a total of 16 reappearances of type-specific
HPV (after two consecutive negative visits) among 100
individuals during the study period. Three reappeared
during pre-HAART, three during post-HAART, and 10
were infected pre-HAART, cleared post-HAART, but
reappeared post-HAART. Although the numbers were
small, there is no significant pattern of reappearance
with or without HAART.
The demographic and baseline clinical characteristics
of the subjects included in this sub-study and the entire
REACH cohort did not differ significantly, as shown in
Table 1. Additionally, self-reported numbers of sex part-
ners in the past three months (39% vs. 34% with no
partner, 36% vs. 40% with 1 partner, 19% vs. 22% with
2-4 partners, and 5% vs. 4% with ≥5 partners) and con-
dom use in the last sexual encounter (62% vs.70% who
said yes) were similar between the participants of this
study and all REACH female participants [31]. The
median follow-up time for HIV-negative participants
was 721.5 days [Interquartile range (IQR) 483-1301]
with 5 [IQR 3-7] visits, and for participants with before/
after HAART initiation crossover study visits, the before
HAART initiation follow-up time was 271 days [IQR
86.5-473] with 2 [IQR 1-3] visits, and after HAART
initiation follow-up time was 427.25 days [IQR 200-871]
with 2.5 [IQR 1-5] visits. In Table 1, CD4+ count seems
to be higher in participants before HAART initiation
than after HAART initiation, but it is noteworthy that
some of the sicker individuals (low CD4+) who were
treated did not have before HAART initiation visits
included in the study. However, among the cross-over
set, there was an increase of CD4+ after HAART initia-
tion (mean increase from 482 to 560 and a median
increase from 471 to 525 cells/mm3 within a six-month
period), indicating an overall immune reconstitution.
As shown in Table 2, type-specific high-risk carcino-
genic HPV baseline prevalence during the before
HAART initiation period ranged from 1-17% and during
the after HAART initiation from 1-18%, and amongst
HIV-negatives, the prevalence ranged from 0.7-10%.
HPV type 58 was the most prevalent at baseline among
HIV-negatives (10%, 95%CI: 5-14%), while HPV 16 was
most prevalent in the before HAART initiation period
(10%, 95%CI: 11-22%) and HPV 53/66 in the after
HAART initiation period (18%, 95%CI: 12-24%). How-
ever, type-specific high-risk carcinogenic HPV cumula-
tive prevalence during the before HAART initiation
period ranged from 6-29% and during the after-HAART
initiation from 4-43%, and amongst HIV-negatives, the
prevalence ranged from 2-26% with possible carcino-
genic HPV type 53/66, and not HPV 16 or HPV 18,
being the most prevalent in all the groups. Among the
low-risk type, HPV 6/11/42/44 had the highest baseline
and overall cumulative prevalence in all three groups.
We note that in both cases of HPV 53/66 and 6/11/42/
44, the detection probes are specific to more than one
HPV and thus could result in the high frequency.
For individual high-risk HPV types, incidence ranged
from 0.64-9.83 cases/100 PY for HPV 67 and HPV53/
66, respectively, among HIV-negatives; from 3.00-12.80
cases/100 PY for HPV 39 and HPV53/66, respectively,
among the HIV-positives in the before HAART initia-
tion period; and from 1.49-17.05 cases/100 PY for HPV
67 and HPV 53/66, respectively, among the HIV-
positives in the after HAART initiation period (Table 2).
Overall, the prevalence and incidence of individual HPV
types tended to be higher among HIV-positive than
HIV-negative individuals; however, the difference was
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statistically significant only for a few HPV types in the
three groups (Table 2).
The absolute CD4+ increased in a majority of the indi-
viduals in the subset analysis of individuals with both
before and after HAART initiation follow-up periods.
However, as shown in Figure 1(a-d), the absolute CD4+
count or the change in CD4+ as a result of immune
reconstitution from HAART therapy did not affect
infections and clearance patterns of individual HPV or
combined carcinogenic HPV types. As a matter of fact,
the prevalence and incidence rates of low-risk HPV
types were similarly higher after HAART initiation than
before HAART initiation. The incidence of high-risk
HPV types 31/33/35, 53/66, 56, 58, 26/69, and 68/70
were all higher than HPV 16, while the incidence of
types 53/66 and 68/70 were higher than HPV 18 in both
before and after HAART initiation periods. Overall, the
results suggest that HAART has no effect on high- or
possible-carcinogenic HPV infections. There were more
counts of infections than clearance in all HPV type
groups except for the most potent carcinogenic HPV 16
strain (high-risk HPV types: 81 infections [in 49 women,
n = 49] versus 39 clearance [n = 26]; possible carcino-
genic HPV types: 51 infections [n = 36] versus 12 clear-
ance [n = 11]; low-risk HPV types: 48 infections
[n = 28] versus 8 clearance [n = 8]; HPV16: 6 infections
[n = 6] versus 9 clearance [n = 9]; HPV18: 11 infections
[n = 11] versus 5 clearance [n = 5]). Of note, the
numbers for clearance were too small during the time
period to stratify and compare either by different vari-
ables or by specific incidence cases.
Discussion
The prevalence of HPV infection in our study subjects is
high: 70% (262/373) at baseline and 70% (78/111)
infected during follow-up, with a cumulative prevalence
of 91% (340/373). This is as expected for a high-risk
cohort of adolescents, judged by their self-reported sex-
ual and other risk behaviors, and for HIV patients in the
U.S. [30]. While clearance of HPV infection is frequent
among HIV-positive adolescents on HAART, continued
acquisition and persistence of HPV infections are com-
mon with and without HAART therapy, as previously
reported [21,26,27,30]. HPV prevalence and incidence
for most types tend to be slightly lower among HIV-
negative than HIV-positive females in general (although
this is not statistically significant in most cases–see
Table 2 footnote); however, our data suggest that there
is no immediate effect of HAART on HIV-infected ado-
lescents, especially with regard to high-risk and vaccine-
type HPV infection prevalence, persistence, or clearance.
Additionally, there is no clear pattern of HPV infection
or clearance with respect to immune reconstitution
(based on CD4+ T-cell counts) from HAART.
The present data corroborate previous findings that
there is no immediate positive effect of HAART on
Table 1 Comparisons of demographics and baseline characteristics of participants stratified by HIV status and HAART
time period in the REACH cohort
Variables Participants
REACH
Females
(n = 411)
REACH HIV-
(n = 146)
All Before HAART
Initiation
(n = 170)
All After HAART
Initiation
(n = 157)
Case-crossover with Both Before and After
HAART Initiation
(n = 100)
Baseline Age
Median [IQR] 17 [16-18] 17 [16-18] 17 [16-18] 17 [16-18] 17 [16-18]
Mean (std dev) 16.25 (1.18) 16.59 (1.21) 17.37 (1.41) 17.42 (1.36) 16.88 (1.12)
Race
African-American 308 (75%) 122 (84%) 132 (78%) 117 (75%) 72 (72%)
European-
American
71 (17%) 20 (14%) 23 (14%) 22 (15%) 19 (19%)
Other 29 (7%) 4 (2%) 15 (8%) 16 (10%) 9 (9%)
Lifetime Sexual
Partner
Median [IQR] 6 [3-11] 5 [3-9] 6 [3-10] 7 [4-11] 6 [4-16]
CD4+ Count (at
Baseline)
Median [IQR] 614.0 [425-
860]
825.5 [672-1016] 516.5 [389-730] 478.5 [344-620] 481 [370-616]
Mean (std dev) 649.8 (310.9) 858.5 (282.21) 557.3 (261.17) 486.4 (244.6) 498.1 (239.5)
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Table 2 Prevalence and incidence of individual HPV types among HIV-negative and HIV-positive adolescent women participating in the REACH study during
the before and after HAART initiation period
ALL Participants Case-crossover with Both Before and After HAART Initiation
Prevalence [95% CI] (%) Incidence [95% CI] (cases/100 person-years) Prevalence [95% CI] (%) Incidence [95% CI] (cases/100
person-years)
HPV Types HIV- n =
146
HIV+ Before
HAART n = 170
HIV+ After HAART
n = 157
HIV- n =
146
HIV+ Before
HAART n = 170
HIV+ After HAART
n = 157
Before HAART
n = 100
After HAART n
= 100
Before HAART
n = 100
After HAART n
= 100
Carcinogenic
HPV 16a, c 6 (2-10) 17 (11-22)*** 10(5-14) 6.83
(3.53-11.96)
6.54
(3.38-11.45)
6.67
(3.45-11.68)
20 (12-28)§§ 7 (2-12) 4.12
(2.13-7.20)
4.64
(2.40-8.12)
HPV18a, c 8 (3-12) 8 (4-12) 6(2-9) 4.66
(2.41-8.15)
6.27
(3.24-10.97)
7.32
(3.78-12.81)
10 (4-16) 4 (0-8) 8.49
(4.39-14.86)
5.72
(2.96-10.02)
HPV39a 0.7 (0-2) 4 (1-7)* 4 (1-8)# 1.93
(0.99-3.37)
3.00
(1.55-5.25)
3.06
(1.58-5.36)
7 (2-12) 3 (0-6) 4.73
(2.45-8.28)
1.50
(0.78-2.63)
HPV45a 2 (0-6) 5 (2-8) 4 (1-8) 3.92
(2.02-6.85)
4.30
(2.23-7.53)
4.66
(2.41-8.16)
5 (1-9) 5 (1-9) 4.55
(2.35-7.97)
3.91
(2.02-6.84)
HPV51a 3 (0-6) 2 (0-5) 3 (0-5) 4.86
(2.51-8.51)
4.67
(2.41-8.17)
4.48
(2.31-7.83)
1 (0-3) 2 (0-5) 4.42
(2.29-7.74)
3.68
(1.90-6.45)
HPV52a 3 (0-5) 10 (5-15) 9 (4-13)# 4.67
(2.41-8.17)
5.02
(2.59-8.78)
5.11
(2.64-8.95)
12 (6-18)§ 4 (0-8) 7.26
(3.76-12.71)
3.17
(1.64-5.55)
HPV56a 2 (0-4) 8 (4-12)* 4 (1-7) 2.60
(1.34-4.56)
5.44
(2.81-9.53)
4.21
(2.18-7.37)
8 (3-13)§ 1 (0-3) 7.14
(3.69-12.49)
5.98
(3.09-10.47)
HPV58a 10 (5-14) 16 (11-22) 10 (5-15) 7.36
(3.80-12.88)
7.71
(3.99-13.49)
7.04
(3.64-12.32)
20 (12-28)§§§ 6 (1-11) 6.93
(3.58-12.13)
5.93
(3.07-10.38)
HPV67b 0.7 (0-2) 1 (0-2) 1 (0-2) 0.64*
(0.33-1.13)
3.75
(1.94-6.56)
1.49
(0.77-2.61)
1 (0-3) 0 3.29
(1.70-5.75)
1.46
(0.76-2.56)
HPV26/69b 2(0-4) 1 (0-3) 3 (0-6) 2.62*
(1.35-4.58)
6.79
(3.51-11.88)
3.43
(1.78-6.01)
0 2 (0-5) 6.60
(3.41-11.55)
5.96
(3.08-10.42)
HPV53/66b 5 (2-9) 12 (7-17)* 18 (12-24)### 9.83
(5.08-17.20)
12.80
(6.62-22.39)
17.05#
(8.82-29.84)
11 (5-17) 12 (6-18) 12.93
(6.68-22.62)
19.49
(10.08-34.10)
HPV68/70b 5 (2-9) 11 (5-15) 13 (8-19)# 7.91
(4.09-13.85)
9.01
(4.66-15.77)
11.30
(5.84-19.77)
15 (8-22) 12 (6-18) 10.36
(5.35-18.12)
12.18
(6.30-21.31)
HPV31/33/35a 8 (4-13) 14 (8-19) 10 (5-15) 6.87
(3.55-12.03)
7.52
(3.89-13.15)
8.85
(4.58-15.49)
13 (6-20) 6 (1-11) 6.34
(3.28-11.10)
7.77
(4.02-13.59)
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Table 2: Prevalence and incidence of individual HPV types among HIV-negative and HIV-positive adolescent women participating in the REACH study during
the before and after HAART initiation period (Continued)
Low Risk
HPV6/11/42/
44c, d
8 (4-13) 14 (8-19) 8 (4-13) 5.30
(2.74-9.27)
7.97
(4.12-13.95)
8.76
(4.53-15.32)
20 (12-28)§ 8 (3-13) 7.59
(3.93-13.29)
8.41
(4.35-14.72)
HPV54/40d 3(0-5) 3 (0-5) 3 (0-6) 5.89 (3.04-
10.31)
8.49
(4.39-14.85)
8.01
(4.14-14.02)
4 (0-8) 1 (0-3) 6.67
(3.45-11.68)
11.11
(5.74-19.44)
HPV13/32d 0.7 (0-2) 1 (0-2) 3 (0-5) 2.24
(1.16-3.92)
4.59
(2.37-8.03)
3.71
(1.92-6.50)
1 (0-3) 3 (0-6) 2.20
(1.14-3.85)
5.14
(2.66-8.99)
HPV62/72d 0.7 (0-2) 1 (0-2) 1 (0-3) 1.60
(0.83-2.80)
2.91
(1.51-5.10)
5.18#
(2.68-9.06)
0 0 1.09§
(0.56-1.91)
7.20
(3.72-12.60)
HPV2/57d 0 1 (0-2) 0 0 0.83
(0.43-1.46)
1.45#
(0.75-2.55)
1 (0-3) 0 0 1.43
(0.74-2.50)
HPV55d 0 0 0 0.96
(0.50-1.68)
1.66
(0.86-2.91)
0.36
(0.19-0.64)
0 0 0 0.71
(0.37-1.25)
a high risk, b probably/possibly carcinogenic, c vaccine type, and d low-risk HPV type; * 0.01 > p > 0.05, **0.05 > p > 0.005, ***0.005 > p - HIV+ before HAART initiation vs hiv-; # 0.01 > p > 0.05, ##0.05 > p > 0.005,
###0.005 > p -HIV+ after HAART initiation vs hiv-; +0.01 > p > 0.05, ++0.05 > p > 0.005, +++0.005 > p - before vs. after HAART initiation; §0.01 > p > 0.05, §§0.05 > p > 0.005, §§§0.005 > p - before vs. after HAART
initiation (with both follow-up).
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high-risk HPV incidence and clearance, despite immune
reconstitution through the increase of CD4+ T-cells
after treatment. On the contrary, we observed higher
prevalence and incidence of possible carcinogenic and
low-risk HPV types in the after HAART initiation per-
iod. Thus, prevention of HPV acquisition is important,
especially in vulnerable populations such as sexually
active adolescents. Recently, the FDA approved Merck’s
HPV vaccine, Gardasil [39], for use in girls and women
aged 9-26, and the European Medicines Agency
approved GlaxoSmithKline’s HPV vaccine, Cervarix [40].
However, since there is no known therapy for HPV
infections, measures to control acquisition or persistence
of HPV infections (mainly other possible carcinogenic
HPV types), especially in HIV/HPV co-infected females,
would reduce the cervical cancer burden. Of note, high-
risk types other than HPV 16 and 18 (targeted in both
vaccines) occurred more frequently in the before and
after HAART initiation periods. Thus, although the vac-
cines might be effective for particular 16 and 18 strains,
innovative approaches are needed to examine cross-pro-
tection against other high-risk types that might be of
epidemic concerns in HIV-positive populations both on
and off HAART. Interestingly, the prevalence of HPV
16 was quite high, but the incidence was not that high
compared to the other types and remained similar
among HIV-negative participants and HIV-positive par-
ticipants before and after HAART. Several studies have
Figure 1 Before (y-axis) and after (x-axis) HAART initiation CD4+ T-cell (CD4+) counts of type-specific new HPV events. CD4+ counts for
all new infections (I) and clearance (C) for a) all high-risk HPV types (I:81 in 49 female adolescents, C:39 in 26 participants); b) possible
carcinogenic types (I:51 in 36 participants, C:12 in 11 infections); c) HPV 16 (I:6 in 6 participants, C:9 in 9 participants); and d) HPV 18 (11 in 11
participants and 5 in 5 participants). For new infections, the before HAART initiation CD4+ count was the mean from all pre-HAART HPV-negative
visits, and the after HAART initiation CD4+ count was the average value of the last post-HAART HPV-negative visit and the first HPV-positive visit.
For clearance, the before HAART initiation CD4+ count was the mean from all pre-HAART HPV-positive visits, and the after HAART initiation CD4+
count was the average value of the last post-HAART HPV-positive visit and the first HPV-negative visit (at least two consecutive HPV-negative
visits).
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reported that the prevalence of HPV 16 was lower in
HIV-positive women than in the general population and
that other high-risk types are also present in these
populations [41]. Most of these studies, however, are
cross-sectional and lack prospective data, even for a
shorter period like ours. While speculative, our data
could indicate that HPV type 16 is more prevalent
among the participants and their partners overall and
thus may be transmitted during the earlier sexual
encounters, whereas other HPV types may be in circula-
tion in this population with higher incidence, but
because they do not persist longer, their cumulative pre-
valence is lower.
The small size of our overall study sample limits our
ability to perform analyses that would fully answer some
relevant questions, such as the impact of HAART on
type-specific clearance and persistence. Thus we present
only counts of clearance rather than the rates. Addition-
ally, the number of visits in which HPV data were
obtained varied considerably from person to person,
both during and before/after HAART initiation period,
and may have introduced a systematic bias. However,
the median number of visits for the two time periods
was similar. The follow-up time periods might be
shorter, especially to detect clearance with two consecu-
tive negative visits, but they are relevant as they span
the initiation of HAART and examine the immediate
effect of HAART. The median follow-up time after
HAART initiation in the study was 427.5 days. Most
(70-90%) HPV infection in healthy women clears
between 12-24 months, and the 13-month follow-up
time may not be long enough to observe a significant
difference and thus may lead to our result. Although we
observed the reconstituted immunity (increase in CD4+
count), it is possible that it may take a longer time to
clear any infection, including HPV. The long-term per-
iod cannot be assessed from this study; however, it
would be important in the future to study the long-term
effect of HAART, especially in adolescents as they live
to adulthood.
Further, it is possible that the use of cervical lavage
samples, rather than cervical exfoliated cells samples,
may have resulted in a slightly lower sensitivity for HPV
detection, although we do not expect this to unduly
affect our study results. Since HPV testing was per-
formed semi-annually, it is possible that a proportion of
infections of less than six-month duration were missed.
Although this may affect the prevalence and incidence
endpoints, more emphasis was placed on evaluation of
HPV infections that persisted, since transient infections
are less frequently associated with significant high-grade
precancerous outcomes. The genotyping of HPV type
was performed using a standard, validated method; how-
ever, some of the types were combined with a common
probe for the analysis. This made it challenging to sepa-
rate some of the HPV types, such as types 6 and 11,
which are included in the quadrivalent HPV vaccine,
from types 42 or 44. Additionally, persistence might be
overestimated if the infections were different at consecu-
tive visits but were detected by the generic probe, but
clearance would be more conservative. However, high-
risk and low-risk types still could be clustered for the
analyses. In essence, participants of the study were high-
risk adolescents, many of whom were likely recently
infected with HPV. Thus, this will likely reduce the bias
of long-term persistence in this population, specifically
among those who were HPV-positive at baseline.
Besides HIV infection, the study participants were co-
infected with other STIs [42], which may cumulatively
or independently affect the immune system separately
from HAART therapy. Although other factors, including
age, sex, race, socio-economic status, smoking status,
health-care, and host genetics, are associated with acqui-
sition and clearance of HPV infection, these variables
were not adjusted due to the small sample size. For
instance, we did not observe any statistically significant
associations (data not shown) with the incidence, preva-
lence, or clearance of type-specific HPV by baseline
smoking status (40% of participants reported ever smok-
ing). While these factors may be important, the present
study focused only on the effect of HAART. All female
adolescents who adhered to their medication were
included and were censored either on the visit-date that
they reported not taking their medication or at the end
of the study. While validation of self-reports is not
always reliable, this seems like an appropriate proxy for
measuring their adherence, given the study design in
this adolescent population. There are reports that Pro-
tease Inhibitor (PI) might inhibit the degradation of p53,
which forms part of the mechanism of HPV persistence;
however, we did not see any significant association of
PI-based HAART (at baseline). Also, several participants
changed their HAART regimen during follow-up, which
makes further analysis of this association difficult, and
the incidence of clearance post-HAART was limited.
Conclusions
Although HAART increases the life expectancy of HIV
patients, it did not show immediate effect on high-risk
and vaccine-type HPV incidence, clearance, and persis-
tence in our study. However, it is very important to
monitor HIV-infected females receiving HAART for a
longer period of time, particularly in regions of the
world where cervical screening is not routinely available.
Additional studies of other possible carcinogenic HPV
types, along with the known HPV 16 and 18, which are
highly prevalent in HIV-positive populations such as
REACH, are also required for effective HPV prevention
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programs. More studies of the impact of HAART and
immune restoration along with medication adherence
on HPV infection and related outcomes are warranted
to guide the development of interventions for such at-
risk adolescents..
Competing interests and Conflicts of interests
The authors declare that they have no competing
interests.
List of abbreviations used
DNA: Deoxyribonucleic acid; FDA: Food Drug Administration; HAART: Highly
Active Antiretroviral Therapy; HIV: Human Immunodeficiency Virus; HPV:
Human Papillomavirus; IQR: Interquartile Range; NHANES: National Health
and Nutrition Examination Survey; PCR: Polymerase Chain Reaction; PY:
Person-years; REACH: Reaching for Excellence in Adolescent Care and
Health; STI: Sexually Transmitted Infection
Acknowledgements
We thank investigators and staff of the Adolescent Medicine HIV/AIDS
Research Network and the youth who participated in the REACH project for
their valuable contributions. The parent study and this sub-study conformed
to the procedures for informed consent (parental permission was obtained
wherever required) approved by institutional review boards at all sponsoring
organizations and to human-experimentation guidelines set forth by the
United States Department of Health and Human Services. The REACH study
was supported by grant U01-HD32830 from National Institute of Child
Health and Human Development. This work was supported in part by a
career developmental award from the Spore in Cervical Cancer
(5P50CA098252-05).
Author details
1Department of Epidemiology, School of Public Health, University of
Alabama at Birmingham, Birmingham, Alabama, USA. 2Department of
Epidemiology, Gillings School of Global Public Health, University of North
Carolina, Chapel Hill, North Carolina, USA. 3WG (Bill) Hefner Medical Center,
Salisbury, North Carolina, USA. 4Wake Forest University Health Sciences,
Winston-Salem, North Carolina, USA.
Authors’ contributions
SSh conceived the idea, supervised the analysis and drafted the manuscript.
SSu conducted the literature search and performed the analysis. JSS, LHB,
CW, and MC-K assisted with the analysis and interpretation of the results. All
authors read and approved the final manuscript.
Received: 4 August 2010 Accepted: 14 October 2010
Published: 14 October 2010
References
1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J,
Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human
papillomavirus in cervical cancer: a worldwide perspective. International
biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer
Inst 1995, 87(11):796-802.
2. Wiley D, Masongsong E: Human papillomavirus: the burden of infection.
Obstet Gynecol Surv 2006, 61(6 Suppl 1):S3-14.
3. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS,
Markowitz LE: Prevalence of HPV infection among females in the United
States. Jama 2007, 297(8):813-819.
4. Weinstock H, Berman S, Cates W Jr: Sexually transmitted diseases among
American youth: incidence and prevalence estimates, 2000. Perspect Sex
Reprod Health 2004, 36(1):6-10.
5. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB: Mathematical
model for the natural history of human papillomavirus infection and
cervical carcinogenesis. Am J Epidemiol 2000, 151(12):1158-1171.
6. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL: The estimated direct
medical cost of sexually transmitted diseases among American youth,
2000. Perspect Sex Reprod Health 2004, 36(1):11-19.
7. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of
cervicovaginal papillomavirus infection in young women. N Engl J Med
1998, 338(7):423-428.
8. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM,
Brescia R, Kanowitz S, Miller SB, et al: The natural history of human
papillomavirus infection as measured by repeated DNA testing in
adolescent and young women. J Pediatr 1998, 132(2):277-284.
9. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A,
Castle PE, Solomon D, Burk R: Rapid clearance of human papillomavirus
and implications for clinical focus on persistent infections. J Natl Cancer
Inst 2008, 100(7):513-517.
10. Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W, Frost A,
Tabara SO, Shah K: Detection of genital human papillomavirus and
associated cytological abnormalities among college women. Sex Transm
Dis 1998, 25(5):243-250.
11. Koshiol J, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM,
Shah KV, Klein RS, Cu-Uvin S, Schuman P, et al: Smoking and time to
clearance of human papillomavirus infection in HIV-seropositive and
HIV-seronegative women. Am J Epidemiol 2006, 164(2):176-183.
12. Lehtinen M, Luukkaala T, Wallin KL, Paavonen J, Thoresen S, Dillner J,
Hakama M: Human papillomavirus infection, risk for subsequent
development of cervical neoplasia and associated population
attributable fraction. J Clin Virol 2001, 22(1):117-124.
13. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K: Cervical
neoplasia and repeated positivity of human papillomavirus infection in
human immunodeficiency virus-seropositive and -seronegative women.
Am J Epidemiol 2000, 151(12):1148-1157.
14. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr: Human
papillomavirus infection in women infected with the human
immunodeficiency virus. N Engl J Med 1997, 337(19):1343-1349.
15. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM,
Shah KV, Klein RS, Cu-Uvin S, Schuman P, et al: Time to clearance of
human papillomavirus infection by type and human immunodeficiency
virus serostatus. Int J Cancer 2006, 119(7):1623-1629.
16. Moscicki AB, Ellenberg JH, Farhat S, Xu J: Persistence of human
papillomavirus infection in HIV-infected and -uninfected adolescent girls:
risk factors and differences, by phylogenetic type. J Infect Dis 2004,
190(1):37-45.
17. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R: A longitudinal
study of human papillomavirus carriage in human immunodeficiency
virus-infected and human immunodeficiency virus-uninfected women.
Am J Obstet Gynecol 1998, 178(5):982-986.
18. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M,
Astemborski J, Daniel R, Shah K: Prevalence, incidence, and type-specific
persistence of human papillomavirus in human immunodeficiency virus
(HIV)-positive and HIV-negative women. J Infect Dis 2001, 184(6):682-690.
19. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and
severity of immunosuppression in persons with AIDS. J Natl Cancer Inst
2007, 99(12):962-972.
20. Bratcher LF, Sahasrabuddhe VV: The impact of antiretroviral therapy on
HPV and cervical intraepithelial neoplasia: current evidence and
directions for future research. Infect Agent Cancer 5:8.
21. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD: Early regression
of cervical lesions in HIV-seropositive women receiving highly active
antiretroviral therapy. Aids 1998, 12(12):1459-1464.
22. Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral
therapy enhances regression of cervical intraepithelial neoplasia in HIV-
seropositive women. Aids 2002, 16(13):1799-1802.
23. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S,
Muderspach L, Burk R, Palefsky J: The effect of highly active antiretroviral
therapy on cervical cytologic changes associated with oncogenic HPV
among HIV-infected women. Aids 2001, 15(16):2157-2164.
24. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H,
Moxley M, Palefsky J, Sacks H, Burk RD, et al: Highly active antiretroviral
therapy and cervical squamous intraepithelial lesions in human
immunodeficiency virus-positive women. J Natl Cancer Inst 2004,
96(14):1070-1076.
Shrestha et al. BMC Infectious Diseases 2010, 10:295
http://www.biomedcentral.com/1471-2334/10/295
Page 10 of 11
25. Robinson WR, Hamilton CA, Michaels SH, Kissinger P: Effect of excisional
therapy and highly active antiretroviral therapy on cervical
intraepithelial neoplasia in women infected with human
immunodeficiency virus. Am J Obstet Gynecol 2001, 184(4):538-543.
26. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastrorilli E,
Taccagni G, Lazzarin A, Uberti-Foppa C: Human papillomavirus infection
and associated cervical disease in human immunodeficiency virus-
infected women: effect of highly active antiretroviral therapy. J Infect Dis
2001, 184(5):547-551.
27. Del Mistro A, Bertorelle R, Franzetti M, Cattelan A, Torrisi A, Giordani MT,
Sposetti R, Bonoldi E, Sasset L, Bonaldi L, et al: Antiretroviral therapy and
the clinical evolution of human papillomavirus-associated genital lesions
in HIV-positive women. Clin Infect Dis 2004, 38(5):737-742.
28. Uberti-Foppa C, Ferrari D, Lodini S, Reina S, Ameglio F, Grasso MA,
Gallotta G, Ferrari A, Taccagni G, Lazzarin A, et al: Long-term effect of
highly active antiretroviral therapy on cervical lesions in HIV-positive
women. Aids 2003, 17(14):2136-2138.
29. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV,
Rompalo AM, Cu-Uvin S, Duerr A: The effect of highly active antiretroviral
therapy on human papillomavirus clearance and cervical cytology.
Obstet Gynecol 2009, 113(1):26-31.
30. De Vuyst H, Lillo F, Broutet N, Smith JS: HIV, human papillomavirus, and
cervical neoplasia and cancer in the era of highly active antiretroviral
therapy. Eur J Cancer Prev 2008, 17(6):545-554.
31. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB: The
REACH (Reaching for Excellence in Adolescent Care and Health) project:
study design, methods, and population profile. J Adolesc Health 2001,
29(3 Suppl):8-18.
32. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ,
Douglas SD, Korber B, Vermund SH, Kaslow RA: Host genetic profiles
predict virological and immunological control of HIV-1 infection in
adolescents. Aids 2002, 16(17):2275-2284.
33. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J,
Vermund SH: The REACH Project of the Adolescent Medicine HIV/AIDS
Research Network: design, methods, and selected characteristics of
participants. J Adolesc Health 1998, 22(4):300-311.
34. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK: Guidelines for Using
Antiretroviral Agents among HIV-Infected Adults and Adolescents: The
Panel on Clinical Practices for Treatment of HIV. Annals of Internal
Medicine 2002, 137(5):381-433.
35. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M: Antiretroviral
medication adherence among the REACH HIV-infected adolescent
cohort in the USA. AIDS Care 2001, 13(1):27-40.
36. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-
Nowick PA, Levin L, Wilson CM: Prevalence of and risks for cervical
human papillomavirus infection and squamous intraepithelial lesions in
adolescent girls: impact of infection with human immunodeficiency
virus. Arch Pediatr Adolesc Med 2000, 154(2):127-134.
37. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007,
90:1-636.
38. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-
Tallaa L, Guha N, Freeman C, Galichet L, et al: A review of human
carcinogens–Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
39. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB,
Bautista OM, Jansen KU, Barr E: Efficacy of human papillomavirus-16
vaccine to prevent cervical intraepithelial neoplasia: a randomized
controlled trial. Obstet Gynecol 2006, 107(1):18-27.
40. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-
Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained
efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine
against human papillomavirus types 16 and 18: follow-up from a
randomised control trial. Lancet 2006, 367(9518):1247-1255.
41. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT,
Ferreccio C, Hieu NT, Matos E, et al: Worldwide distribution of human
papillomavirus types in cytologically normal women in the International
Agency for Research on Cancer HPV prevalence surveys: a pooled
analysis. Lancet 2005, 366(9490):991-998.
42. Vermund SH, Wilson CM, Rogers AS, Partlow C, Moscicki AB: Sexually
transmitted infections among HIV infected and HIV uninfected high-risk
youth in the REACH study. Reaching for Excellence in Adolescent Care
and Health. J Adolesc Health 2001, 29(3 Suppl):49-56.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/295/prepub
doi:10.1186/1471-2334-10-295
Cite this article as: Shrestha et al.: The impact of highly active
antiretroviral therapy on prevalence and incidence of cervical human
papillomavirus infections in HIV-positive adolescents. BMC Infectious
Diseases 2010 10:295.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shrestha et al. BMC Infectious Diseases 2010, 10:295
http://www.biomedcentral.com/1471-2334/10/295
Page 11 of 11
